Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Tax Provisions (2023 - 2025)

Arcutis Biotherapeutics has reported Tax Provisions over the past 3 years, most recently at $499000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions rose 54.49% year-over-year to $499000.0; the TTM value through Dec 2025 reached $1.2 million, up 85.47%, while the annual FY2025 figure was $1.2 million, 85.47% up from the prior year.
  • Tax Provisions for Q4 2025 was $499000.0 at Arcutis Biotherapeutics, up from $80000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $3.0 million in Q3 2023 and troughed at $12000.0 in Q4 2023.
  • A 3-year average of $610250.0 and a median of $323500.0 in 2024 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: soared 2591.67% in 2024 and later decreased 13.89% in 2025.
  • Year by year, Tax Provisions stood at $12000.0 in 2023, then soared by 2591.67% to $323000.0 in 2024, then soared by 54.49% to $499000.0 in 2025.
  • Business Quant data shows Tax Provisions for ARQT at $499000.0 in Q4 2025, $80000.0 in Q3 2025, and $342000.0 in Q2 2025.